2 results
Not approvedWill not start
Main objective:To improve the functional neurological outcome of patients, as measured on the Raschbuilt Overall Disability Scale (RODS) for inflammatory neuropathies (iRODS) with Zanubrutinib in combination with standard treatment with Rituximab or…
Approved WMOPending
The aim of this research is:1. To test the safety of MK-1308A, MK-4280A, MK-7684A and MK 4830 + pembrolizumab against pembrolizumab as the single agent.2. To test how well MK-1308A, MK-4280A, MK-7684A and MK-4830 + pembrolizumab are tolerated by…